Dexmedetomidine for Sedation During Radiological Interventional Procedures

National Cancer Institute, Egypt40 enrolled

Overview

Evaluation of the role of dexmedetomidine as a sole agent in sedating patients undergoing interventional radiological procedures and measuring its different outcome variables.

Study Type

INTERVENTIONAL

Allocation

Purpose

TREATMENT

Masking

NONE

Enrollment

Conditions

Procedural Sedation

Interventions

DexmeditomedineDRUG

Eligibility

Sex: ALLMin age: 18 YearsMax age: 65 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Age from 18-65 years old * ASA physical status of I-II * Expected procedure lasting at least 30 minutes Exclusion Criteria: * Unstable cardiac status (life-threatening arrhythmias, abnormal cardiac anatomy, significant cardiac dysfunction and third-degree heart block. * An alpha2-agonist or antagonist within 14 days before the scheduled procedure. * patients received an IV opioid within 1 h, or an oral or IM opioid within 4 h of the start of study drug administration. * Patients who are allergic to Dexmedetomidine or alpha 2-agonists.

Locations (1)

National Cancer Institute-Egypt

Cairo, Egypt

Outcomes

Primary Outcomes

Degree of sedation

It will be measured and recorded by using the Ramsay sedation score.

Time frame: 1 hour

verbal analogue scale

assessment of pain using VAS score

Time frame: 1 hour

Secondary Outcomes

patient satisfaction

assessment of patient satisfaction by 4 point scale

Time frame: 24 hours

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.